Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This phase III trial is studying how well combination chemotherapy followed by second-look surgery and radiation therapy works in treating children with nonmetastatic medulloblastoma or primitive neuroectodermal tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with surgery and radiation therapy may kill more tumor cells.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Oncology Group
• Collaborator: National Cancer Institute (NCI)
• Treatments: Cisplatin; Cyclophosphamide; Etoposide; Etoposide phosphate; Vincristine

Criteria

Inclusion Criteria:

• Histologically confirmed primary medulloblastoma or posterior fossa primitive neuroectodermal tumor

• Prior definitive tumor resection within 6 weeks of study

• No evidence of metastases

• Hemoglobin at least 10 g/dL

• Absolute neutrophil count at least 1,500/mm3

• Platelet count at least 100,000/mm3

• AST less than 2.5 times normal

• Bilirubin less than 1.5 mg/dL

• Creatinine less than 1.2 mg/dL

• Creatinine clearance greater than 70 mL/min

• No prior chemotherapy

• No prior radiotherapy

• See Disease Characteristics